Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.

Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska MM, Abruzzese E, Annunziata M, Stagno F, Tiribelli M, Binotto G, Bonifacio M, Fava C, Iurlo A, Bucelli C, Mansueto G, Gozzini A, Falzetti F, Montefusco E, Crisà E, Gugliotta G, Russo S, Cedrone M, RussoRossi A, Pregno P, Isidori A, Mauro E, Atelda R, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Galimberti S, Orlandi E, Calistri E, Bocchia M, Cavazzini F, Rege Cambrin G, Orofino N, Luciano L, Sgherza N, Rosti G, Latagliata R, Capodanno I.

Ann Hematol. 2019 Aug 7. doi: 10.1007/s00277-019-03767-y. [Epub ahead of print]

PMID:
31392461
2.

Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention.

Caocci G, Mulas O, Bonifacio M, Abruzzese E, Galimberti S, Orlandi EM, Iurlo A, Annunziata M, Luciano L, Castagnetti F, Gozzini A, Stagno F, Binotto G, Pregno P, Albano F, Martino B, Fozza C, Scaffidi L, Trawinska MM, Baratè C, Elena C, Cattaneo D, Scalzulli E, La Nasa G, Foà R, Breccia M.

Int J Cardiol. 2019 Aug 1;288:124-127. doi: 10.1016/j.ijcard.2019.04.051. Epub 2019 Apr 17.

PMID:
31029498
3.

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.

Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Sgherza N, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Gugliotta G, Baratè C, Scaffidi L, Elena C, Pirillo F, Scalzulli E, La Nasa G, Foà R, Breccia M.

Hematol Oncol. 2019 Mar 20. doi: 10.1002/hon.2606. [Epub ahead of print]

PMID:
30892724
4.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

5.

Targeting chronic myeloid leukemia stem cells with ERK5 pathway inhibitors.

4° JOINT MEETING OF PATHOLOGY AND LABORATORY MEDICINE SIPMET–SIPMEL - SECOND JOINT MEETING IN COLLABORATION WITH ASIP–AMP–UEMS–WASPALM - 4° SIPMEL NATIONAL CONGRESS - 34° SIPMET NATIONAL CONGRESS - 4° CONGRESS OF PATHOLOGY AND LABORATORY MEDICINE, Tusa I, Cheloni G, Poteti M, Gozzini A, Deng X, Gray NS, Li S, Dello Sbarba P, Rovida E.

J Biol Regul Homeost Agents. 2018 Jul-Aug;32(4 Suppl. 1):36. No abstract available.

PMID:
30810012
6.

Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia.

Raspadori D, Pacelli P, Sicuranza A, Abruzzese E, Iurlo A, Cattaneo D, Gozzini A, Galimberti S, Baratè C, Pregno P, Nicolosi M, Sorà F, Annunziata M, Luciano L, Caocci G, Moretti S, Sgherza N, Fozza C, Russo S, Usala E, Liberati MA, Ciofini S, Trawinska MM, Gozzetti A, Bocchia M.

Cytometry B Clin Cytom. 2019 Jul;96(4):294-299. doi: 10.1002/cyto.b.21764. Epub 2019 Feb 3.

PMID:
30714299
7.

Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells.

Tusa I, Cheloni G, Poteti M, Gozzini A, DeSouza NH, Shan Y, Deng X, Gray NS, Li S, Rovida E, Dello Sbarba P.

Stem Cell Reports. 2018 Oct 9;11(4):929-943. doi: 10.1016/j.stemcr.2018.08.016. Epub 2018 Sep 20.

8.

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, Galimberti S, Aprile L, Martino B, Pregno P, Sorà F, Alunni G, Fava C, Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Baratè C, Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M, Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D.

Front Oncol. 2018 May 30;8:194. doi: 10.3389/fonc.2018.00194. eCollection 2018.

9.

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.

Breccia M, Efficace F, Iurlo A, Luciano L, Abruzzese E, Gozzini A, Pregno P, Tiribelli M, Rosti G, Minotti G.

Expert Opin Drug Saf. 2018 Jun;17(6):623-628. doi: 10.1080/14740338.2018.1480719. Epub 2018 May 30. Review.

PMID:
29845876
10.

Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.

Breccia M, Abruzzese E, Castagnetti F, Bonifacio M, Gangemi D, Sorà F, Iurlo A, Luciano L, Gozzini A, Gentile M, Bocchia M, Luzi D, Maggi A, Sgherza N, Isidori A, Crugnola M, Pregno P, Scortechini AR, Capodanno I, Pizzuti M, Foà R.

Ann Hematol. 2018 Sep;97(9):1577-1580. doi: 10.1007/s00277-018-3337-2. Epub 2018 Apr 19.

PMID:
29675611
11.

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.

Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, De Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, La Nasa G, Foà R, Breccia M.

Am J Hematol. 2018 Jul;93(7):E159-E161. doi: 10.1002/ajh.25102. Epub 2018 Apr 28. No abstract available.

12.

Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures.

Masala E, Valencia-Martinez A, Pillozzi S, Rondelli T, Brogi A, Sanna A, Gozzini A, Arcangeli A, Sbarba PD, Santini V.

Oncotarget. 2018 Jan 24;9(12):10561-10571. doi: 10.18632/oncotarget.24302. eCollection 2018 Feb 13.

13.

Late-Onset Hepatic Veno-Occlusive Disease after Allografting: Report of Two Cases with Atypical Clinical Features Successfully Treated with Defibrotide.

Castellino A, Guidi S, Dellacasa CM, Gozzini A, Donnini I, Nozzoli C, Manetta S, Aydin S, Giaccone L, Festuccia M, Brunello L, Maffini E, Bruno B, David E, Busca A.

Mediterr J Hematol Infect Dis. 2018 Jan 1;10(1):e2018001. doi: 10.4084/MJHID.2018.001. eCollection 2018.

14.

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.

Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A.

Oncotarget. 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20.

15.

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.

Iurlo A, Galimberti S, Abruzzese E, Annunziata M, Bonifacio M, Latagliata R, Pregno P, Ferrero D, Sorà F, Orlandi EM, Fava C, Cattaneo D, Bucelli C, Binotto G, Pungolino E, Tiribelli M, Gozzini A, Gugliotta G, Castagnetti F, Stagno F, Rege-Cambrin G, Martino B, Luciano L, Breccia M, Sica S, Bocchia M, Pane F, Saglio G, Rosti G, Specchia G, Cortelezzi A, Baccarani M.

Ann Hematol. 2018 Jan;97(1):95-100. doi: 10.1007/s00277-017-3144-1. Epub 2017 Oct 2.

PMID:
28971265
16.

Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.

Cheloni G, Tanturli M, Tusa I, Ho DeSouza N, Shan Y, Gozzini A, Mazurier F, Rovida E, Li S, Dello Sbarba P.

Blood. 2017 Aug 3;130(5):655-665. doi: 10.1182/blood-2016-10-745588. Epub 2017 Jun 2.

17.

Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia.

Valencia-Martinez A, Sanna A, Masala E, Contini E, Brogi A, Gozzini A, Santini V.

Haematologica. 2017 Sep;102(9):e332-e335. doi: 10.3324/haematol.2017.166124. Epub 2017 May 18. No abstract available.

18.

The missed Constitutional Reform and its possible impact on the sustainability of the Italian National Health Service.

Signorelli C, Odone A, Gozzini A, Petrelli F, Tirani M, Zangrandi A, Zoni R, Florindo N.

Acta Biomed. 2017 Apr 28;88(1):91-94. doi: 10.23750/abm.v88i1.6408.

19.

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome.

Sora F, Iurlo A, Sica S, Latagliata R, Annunziata M, Galimberti S, Castagnetti F, Pregno P, Sgherza N, Celesti F, Bocchia M, Gozzini A, Fava C, Cattaneo D, Crugnola M, Montefusco E, Mauro E, Capodanno I, Breccia M.

Br J Haematol. 2018 Apr;181(2):267-270. doi: 10.1111/bjh.14553. Epub 2017 Feb 7. No abstract available.

PMID:
28169426
20.

[Re-organization of health services in Italy and the role of medical directors of hospitals and local health units].

Signorelli C, Ciorba V, Pezzetti F, Odone A, Gozzini A, Zangrandi A.

Ig Sanita Pubbl. 2016 Jul-Ago;72(4):371-384. Review. Italian.

PMID:
27783609
21.

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.

Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, Fava C, Gozzini A, Bonifacio M, Sorà F, Leonetti Crescenzi S, Bocchia M, Crugnola M, Castagnetti F, Capodanno I, Galimberti S, Feo C, Porrini R, Pregno P, Rizzo M, Antolino A, Mauro E, Sgherza N, Luciano L, Tiribelli M, Russo Rossi A, Trawinska M, Vigneri P, Breccia M, Rosti G, Alimena G.

Neoplasia. 2016 Sep;18(9):536-40. doi: 10.1016/j.neo.2016.07.005.

22.

Flu vaccination in elite athletes: A survey among Serie A soccer teams.

Signorelli C, Odone A, Miduri A, Cella P, Pasquarella C, Gozzini A, Tamburrino P, Castellacci E.

Acta Biomed. 2016 Sep 13;87(2):117-20.

PMID:
27648991
23.

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.

Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A.

Oncotarget. 2016 Nov 29;7(48):80083-80090. doi: 10.18632/oncotarget.11657.

24.

Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.

Bocchia M, Galimberti S, Aprile L, Sicuranza A, Gozzini A, Santilli F, Abruzzese E, Baratè C, Scappini B, Fontanelli G, Trawinska MM, Defina M, Gozzetti A, Bosi A, Petrini M, Puccetti L.

Oncotarget. 2016 Nov 1;7(44):72311-72321. doi: 10.18632/oncotarget.11100.

25.

Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.

Breccia M, Abruzzese E, Iurlo A, Gozzini A, Isidori A, Gangemi D, Pregno P, Alimena G.

Haematologica. 2016 Jun;101(6):e267-8. doi: 10.3324/haematol.2016.145623. Epub 2016 May 31. No abstract available.

26.

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Gozzini A, Usala E, Carella AM, Rege-Cambrin G, Martino B, Abruzzese E, Albano F, Stagno F, Luciano L, D'Adda M, Bocchia M, Cavazzini F, Tiribelli M, Lunghi M, Pia Falcone A, Musolino C, Levato L, Venturi C, Soverini S, Cavo M, Alimena G, Pane F, Martinelli G, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Am J Hematol. 2016 Jun;91(6):617-22. doi: 10.1002/ajh.24362. Epub 2016 Apr 24.

27.

Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells.

Del Poggetto E, Tanturli M, Ben-Califa N, Gozzini A, Tusa I, Cheloni G, Marzi I, Cipolleschi MG, Kashman Y, Neumann D, Rovida E, Dello Sbarba P.

Cell Cycle. 2015;14(19):3146-54. doi: 10.1080/15384101.2015.1078029.

28.

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.

Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, Gobbi M, Carella AM, Gozzini A, Usala E, Cavazzini F, Danise P, Tiribelli M, Binotto G, Pregno P, Bocchia M, Gaidano G, Crugnola M, Bonifacio M, Avanzini P, Celesti F, Guella A, Martino B, Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E, Gambacorti-Passerini C, Alimena G.

Leuk Res. 2015 Oct;39(10):1055-9. doi: 10.1016/j.leukres.2015.07.004. Epub 2015 Jul 14.

PMID:
26282944
29.

Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.

Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, Elena C, Pierri I, Assouline S, D'Emilio A, Gozzini A, Giraldo P, Stagno F, Iurlo A, Luciani M, De Riso G, Redaelli S, Kim DW, Pirola A, Mezzatesta C, Petroccione A, Lodolo D'Oria A, Crivori P, Piazza R, Gambacorti-Passerini C.

Am J Hematol. 2015 Oct;90(10):910-4. doi: 10.1002/ajh.24120. Epub 2015 Sep 10.

30.

Human Preosteoblastic Cell Culture from a Patient with Severe Tumoral Calcinosis-Hyperphosphatemia Due to a New GALNT3 Gene Mutation: Study of In Vitro Mineralization.

Masi L, Beltrami G, Ottanelli S, Franceschelli F, Gozzini A, Zonefrati R, Galli G, Ciuffi S, Mavilia C, Giusti F, Marcucci G, Cioppi F, Colli E, Fossi C, Franchi A, Casentini C, Capanna R, Brandi ML.

Calcif Tissue Int. 2015 May;96(5):438-52. doi: 10.1007/s00223-015-9974-8. Epub 2015 Apr 23.

PMID:
25899975
31.

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; GIMEMA CML Working Party.

Ann Oncol. 2015 Jan;26(1):185-92. doi: 10.1093/annonc/mdu490. Epub 2014 Oct 30.

PMID:
25361995
32.

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.

Breccia M, Luciano L, Latagliata R, Castagnetti F, Ferrero D, Cavazzini F, Trawinska MM, Annunziata M, Stagno F, Tiribelli M, Binotto G, Crisà E, Musto P, Gozzini A, Cavalli L, Montefusco E, Iurlo A, Russo S, Cedrone M, Rossi AR, Pregno P, Endri M, Spadea A, Molica M, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Cambrin GR, Isidori A, Sica S, Abruzzese E, Speccha G, Rosti G, Alimena G.

Leuk Res. 2014 Oct;38(10):1173-6. doi: 10.1016/j.leukres.2014.06.020. Epub 2014 Jul 7.

PMID:
25047978
33.

Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.

Breccia M, Alimena G, Baccarani M, Bocchia M, Di Raimondo F, Gambacorti-Passerini C, Gozzini A, Morra E, Pane F, Pregno P, Rege-Cambrin G, Rosti G, Specchia G, Vigneri P, Saglio G.

Crit Rev Oncol Hematol. 2014 Jun;90(3):181-9. doi: 10.1016/j.critrevonc.2013.12.010. Epub 2013 Dec 17.

PMID:
24405858
34.

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.

Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, Luppi M, Bresciani P, Salvucci M, Russo D, Sica S, Orlandi E, Intermesoli T, Gozzini A, Bonifacio M, Rigolin GM, Pane F, Baccarani M, Cavo M, Martinelli G.

Cancer. 2014 Apr 1;120(7):1002-9. doi: 10.1002/cncr.28522. Epub 2013 Dec 30.

35.

Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.

Buchi F, Masala E, Rossi A, Valencia A, Spinelli E, Sanna A, Gozzini A, Santini V.

Epigenetics. 2014 Mar;9(3):387-95. doi: 10.4161/epi.27322. Epub 2013 Dec 2.

36.

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

Valencia A, Masala E, Rossi A, Martino A, Sanna A, Buchi F, Canzian F, Cilloni D, Gaidano V, Voso MT, Kosmider O, Fontenay M, Gozzini A, Bosi A, Santini V.

Leukemia. 2014 Mar;28(3):621-8. doi: 10.1038/leu.2013.330. Epub 2013 Nov 6.

37.

Stiff skin syndrome and myeloma successfully treated with autologous haematopoietic stem cell transplantation (HSCT).

Bandinelli F, Saccardi R, Salvadorini G, Bosi A, Gozzini A, Matucci Cerinic M.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):181-3. Epub 2013 Jul 23.

PMID:
23910622
38.

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.

Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, Fava C, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Montefusco E, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Storti S, D'Addosio A, Rege-Cambrin G, Luciano L, Alimena G.

Drugs Aging. 2013 Aug;30(8):629-37. doi: 10.1007/s40266-013-0088-6.

PMID:
23681399
39.

Can fibroblast growth factor (FGF)-23 circulating levels suggest coronary artery abnormalities in children with Kawasaki disease?

Masi L, Franceschelli F, Leoncini G, Gozzini A, Rigante D, La Torre F, Matucci-Cerinic M, Brandi ML, Falcini F.

Clin Exp Rheumatol. 2013 Jan-Feb;31(1):149-53. Epub 2013 Jan 16.

PMID:
23324126
40.

Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.

Barbetti V, Gozzini A, Cheloni G, Marzi I, Fabiani E, Santini V, Dello Sbarba P, Rovida E.

Epigenetics. 2013 Feb;8(2):210-9. doi: 10.4161/epi.23538. Epub 2013 Jan 15. Erratum in: Epigenetics. 2013 Dec;8(12):1384.

41.

Identification of a novel p190-derived breakpoint Peptide suitable for Peptide vaccine therapeutic approach in ph+ acute lymphoblastic leukemia patients.

Ippoliti M, Defina M, Gozzini A, Baratè C, Aprile L, Pietrini A, Gozzetti A, Raspadori D, Lauria F, Bocchia M.

Leuk Res Treatment. 2012;2012:150651. doi: 10.1155/2012/150651. Epub 2012 Feb 15.

42.

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.

Tiribelli M, Latagliata R, Luciano L, Castagnetti F, Gozzini A, Cambrin GR, Annunziata M, Stagno F, Pregno P, Albano F, Abruzzese E, Musto P, Montefusco E, Fava C, Fanin R, Pane F, Rosti G, Breccia M, Alimena G, Vigneri P.

Ann Hematol. 2013 Jan;92(2):179-83. doi: 10.1007/s00277-012-1591-2. Epub 2012 Oct 10.

PMID:
23053188
43.

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.

Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G.

Hematol Oncol. 2013 Jun;31(2):103-9. doi: 10.1002/hon.2020. Epub 2012 Jul 19. Erratum in: Hematol Oncol. 2013 Spe;31(3):169.

PMID:
22815278
44.

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.

Russo Rossi A, Breccia M, Abruzzese E, Castagnetti F, Luciano L, Gozzini A, Annunziata M, Martino B, Stagno F, Cavazzini F, Tiribelli M, Visani G, Pregno P, Musto P, Fava C, Sgherza N, Albano F, Rosti G, Alimena G, Specchia G.

Haematologica. 2013 Mar;98(3):399-403. doi: 10.3324/haematol.2012.064337. Epub 2012 Jul 16.

45.

Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells.

Masala E, Valencia A, Buchi F, Nosi D, Spinelli E, Gozzini A, Sassolini F, Sanna A, Zecchi S, Bosi A, Santini V.

Leuk Res. 2012 Oct;36(10):1290-5. doi: 10.1016/j.leukres.2012.05.023. Epub 2012 Jun 27.

PMID:
22742816
46.

Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.

Defina M, Ippoliti M, Gozzetti A, Abruzzese E, Castagnetti F, Crupi R, Tiribelli M, Breccia M, Salvucci M, Aprile L, Baratè C, Gozzini A, Rosti G, Lauria F, Bocchia M.

Cancer. 2012 Nov 1;118(21):5265-9. doi: 10.1002/cncr.27506. Epub 2012 Apr 19.

47.

Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.

Spinelli E, Caporale R, Buchi F, Masala E, Gozzini A, Sanna A, Sassolini F, Valencia A, Bosi A, Santini V.

Clin Cancer Res. 2012 Jun 1;18(11):3079-89. doi: 10.1158/1078-0432.CCR-11-0686. Epub 2012 Apr 11.

48.

A novel germline inactivating mutation in the CASR gene in an Italian kindred affected by familial hypocalciuric hypercalcemia.

Falchetti A, Gozzini A, Terranegra A, Soldati L, Vezzoli G, Leoncini G, Giusti F, Franceschelli F, Masi L, Tanini A, Cavalli L, Brandi ML.

Eur J Endocrinol. 2012 May;166(5):933-40. doi: 10.1530/EJE-11-0953. Epub 2012 Feb 7.

PMID:
22315359
49.

Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine.

Buchi F, Spinelli E, Masala E, Gozzini A, Sanna A, Bosi A, Ferrari G, Santini V.

Leuk Res. 2012 May;36(5):607-18. doi: 10.1016/j.leukres.2011.11.024. Epub 2012 Jan 9.

PMID:
22230298
50.

[Guidelines for immunization practices in professional athletes].

Signorelli C, Gozzini A.

Ig Sanita Pubbl. 2011 May-Jun;67(3):387-400. Italian.

PMID:
22033165

Supplemental Content

Loading ...
Support Center